Abstract 128P
Background
Tislelizumab, an investigational monoclonal antibody with high affinity and specificity for PD-1, was engineered to minimize binding to FcγR on macrophages in order to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti-PD-1 therapy. In prior reports, tislelizumab, as a single agent and in combination with various chemotherapies, was generally well tolerated and had antitumor activity in pts with advanced solid tumors. This phase 2 study (NCT03469557) assessed tislelizumab plus chemotherapy as first-line therapy in pts with inoperable, locally advanced, or metastatic GC/GEJC or ESCC.
Methods
Patients with GC/GEJC received tislelizumab (200 mg IV Q3W) + oxaliplatin (130 mg/m2 IV Q3W for ≤6 cycles) and capecitabine (1000 mg/m2, Days 1-15 orally BID Q3W); pts with ESCC received tislelizumab + cisplatin (80 mg/m2 IV Q3W for ≤6 cycles) and 5FU (800 mg/m2/d, Days 1-5 IV Q3W for ≤6 cycles). Response was assessed using RECIST v1.1, Kaplan-Meier analysis estimated survival, and adverse event (AE) monitoring examined safety/tolerability.
Results
As of 31 Mar 2019, 30 pts with GC/GEJC and ESCC (n = 15 each) were enrolled. Median age was 61 yr; most pts were male (n = 25). Clinical responses were observed during treatment (Table). In pts with ESCC, treatment-emergent AEs (TEAEs) of grade ≥3 occurring in ≥ 2 pts were vomiting and dysphagia (n = 4 each), hyponatremia (n = 3), and anemia, leukopenia, fatigue, lung infection, and decreased weight (n = 2 each). No grade ≥3 TEAEs occurred in ≥ 2 pts with GC/GEJC. One pt with ESCC had a fatal AE (hepatic dysfunction) attributed to treatment by the investigator, but which may have been confounded by progressive disease and underlying hepatitis.Table:
128P
GC/GEJC (n = 15) | ESCC (n = 15) | |
---|---|---|
PR, n (%) | 7 (46.7) | 7 (46.7) |
SD, n (%) | 3 (20.0) | 5 (33.3) |
PD, n (%) | 1 (6.7) | 0 (0.0) |
Non-CR/non-PD, n (%)* | 2 (13.3) | 0 (0.0) |
NE, n (%) | 2 (13.3) | 3 (20.0) |
ORR, % (95% CI) | 46.7 (21.3, 73.4) | 46.7 (21.3, 73.4) |
Median DoR, (95% CI) | NR (3.0, NR) | 12.8 (3.5, 12.8) |
Median PFS, mo (95% CI) | 6.1 (3.8, NR) | 10.4 (5.6, 15.1) |
Median OS, mo (95% CI) | NR (7.0, NR) | NR (5.6, NR) |
Median follow-up, mo (95% CI) | 15.4 (14.7, 17.2) | 13.0 (12.3, 14.0) |
Patients who have non-target lesions at baseline.
Abbreviations: CI, confidence interval; CR, complete response; DoR, duration of response; ESCC, esophageal squamous cell carcinoma; GC/GEJC, gastric/gastroesophageal junction cancer; mo, month; NE, not evaluable; NR, not reached; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.
Conclusions
Tislelizumab plus chemotherapy was generally well tolerated and antitumor activity was observed in pts with advanced GC/GEJC or ESCC.
Clinical trial identification
NCT03469557.
Editorial acknowledgement
Writing and editorial support for this abstract was provided by Agnieszka Laskowski, PhD, and Elizabeth Hermans, PhD, of OPEN Health Medical Communications (Chicago, IL).
Legal entity responsible for the study
BeiGene Co., Ltd., Beijing, China.
Funding
BeiGene (Beijing) Co., Ltd., Beijing, China.
Disclosure
X. Li: Full / Part-time employment: BeiGene (Beijing) Co., Ltd. Y. Li: Full / Part-time employment: BeiGene (Beijing) Co., Ltd. X. Wang: Full / Part-time employment: BeiGene (Beijing) Co., Ltd. S. Yang: Full / Part-time employment: BeiGene (Beijing) Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract